Merck & Co., Inc. (NYSE:MRK) Shares Sold by Carnegie Capital Asset Management LLC

Carnegie Capital Asset Management LLC reduced its stake in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 22.2% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 29,873 shares of the company’s stock after selling 8,505 shares during the quarter. Carnegie Capital Asset Management LLC’s holdings in Merck & Co., Inc. were worth $2,323,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Norges Bank acquired a new position in Merck & Co., Inc. during the fourth quarter worth about $1,823,028,000. BlackRock Inc. grew its position in shares of Merck & Co., Inc. by 5.5% in the fourth quarter. BlackRock Inc. now owns 198,224,263 shares of the company’s stock valued at $15,191,909,000 after purchasing an additional 10,326,974 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Merck & Co., Inc. by 2,671.4% in the first quarter. Renaissance Technologies LLC now owns 5,099,334 shares of the company’s stock valued at $418,400,000 after purchasing an additional 4,915,334 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Merck & Co., Inc. by 2.3% in the first quarter. Vanguard Group Inc. now owns 216,096,057 shares of the company’s stock valued at $17,730,682,000 after purchasing an additional 4,893,526 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its position in shares of Merck & Co., Inc. by 256.3% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 4,882,173 shares of the company’s stock valued at $400,582,000 after purchasing an additional 3,511,900 shares during the last quarter. 73.33% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $84.53 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. The company has a market cap of $214.14 billion, a P/E ratio of 12.94, a P/E/G ratio of 1.16 and a beta of 0.33. Merck & Co., Inc. has a fifty-two week low of $71.50 and a fifty-two week high of $95.72. The firm’s 50 day moving average is $88.96 and its two-hundred day moving average is $87.74.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings results on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.20. The company had revenue of $14.59 billion for the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. Merck & Co., Inc.’s revenue was up 28.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.31 earnings per share. Analysts expect that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be paid a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is presently 42.27%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on MRK shares. Berenberg Bank upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and increased their price target for the company from $95.00 to $100.00 in a research report on Wednesday, September 14th. Cowen increased their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research report on Monday, June 27th. Erste Group Bank upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday, August 25th. Mizuho began coverage on shares of Merck & Co., Inc. in a research report on Friday, June 24th. They issued a “buy” rating and a $100.00 price target on the stock. Finally, Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research report on Friday, July 29th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $98.28.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.